Cargando…

Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study

BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ja Kyung, Kim, Jun Won, Lee, Ik Jae, Joo, Seung-Moon, Lee, Kwang-Hun, Cho, Eun-Suk, Yu, Jeong-Sik, Jeon, Tae Joo, Kim, Yonsoo, Lee, Jung Il, Lee, Kwan Sik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558652/
https://www.ncbi.nlm.nih.gov/pubmed/28810886
http://dx.doi.org/10.1186/s13014-017-0873-1
_version_ 1783257418881302528
author Kim, Ja Kyung
Kim, Jun Won
Lee, Ik Jae
Joo, Seung-Moon
Lee, Kwang-Hun
Cho, Eun-Suk
Yu, Jeong-Sik
Jeon, Tae Joo
Kim, Yonsoo
Lee, Jung Il
Lee, Kwan Sik
author_facet Kim, Ja Kyung
Kim, Jun Won
Lee, Ik Jae
Joo, Seung-Moon
Lee, Kwang-Hun
Cho, Eun-Suk
Yu, Jeong-Sik
Jeon, Tae Joo
Kim, Yonsoo
Lee, Jung Il
Lee, Kwan Sik
author_sort Kim, Ja Kyung
collection PubMed
description BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy. After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were analyzed. RESULTS: The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response (OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months, P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an OR after CCRT or additional TACE. CONCLUSION: Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A further prospective study is needed to confirm the positive effect of additional TACE after CCRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-017-0873-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5558652
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55586522017-08-16 Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study Kim, Ja Kyung Kim, Jun Won Lee, Ik Jae Joo, Seung-Moon Lee, Kwang-Hun Cho, Eun-Suk Yu, Jeong-Sik Jeon, Tae Joo Kim, Yonsoo Lee, Jung Il Lee, Kwan Sik Radiat Oncol Research BACKGROUND: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy (HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess the factors affecting survival after CCRT, including additional TACE during repeated HAIC. METHODS: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy. After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were analyzed. RESULTS: The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response (OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months, P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an OR after CCRT or additional TACE. CONCLUSION: Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A further prospective study is needed to confirm the positive effect of additional TACE after CCRT. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13014-017-0873-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-15 /pmc/articles/PMC5558652/ /pubmed/28810886 http://dx.doi.org/10.1186/s13014-017-0873-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kim, Ja Kyung
Kim, Jun Won
Lee, Ik Jae
Joo, Seung-Moon
Lee, Kwang-Hun
Cho, Eun-Suk
Yu, Jeong-Sik
Jeon, Tae Joo
Kim, Yonsoo
Lee, Jung Il
Lee, Kwan Sik
Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title_full Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title_fullStr Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title_full_unstemmed Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title_short Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
title_sort factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558652/
https://www.ncbi.nlm.nih.gov/pubmed/28810886
http://dx.doi.org/10.1186/s13014-017-0873-1
work_keys_str_mv AT kimjakyung factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT kimjunwon factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT leeikjae factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT jooseungmoon factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT leekwanghun factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT choeunsuk factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT yujeongsik factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT jeontaejoo factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT kimyonsoo factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT leejungil factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy
AT leekwansik factorsaffectingsurvivalafterconcurrentchemoradiationtherapyforadvancedhepatocellularcarcinomaaretrospectivestudy